Nasdaq · CIK 0002123613
KARD Kardigan, Inc.
Insider trading from SEC Form 4. Last filing 12 d ago. Close $14.67 on Oct 9, 2026, +9% from the 52-week low and -43% from the high.
Kardigan, Inc. (KARD) has 6 SEC Form 4 filings on file from 4 insiders, the latest filed on Oct 1, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
2 open-market trades have been scored at KARD. The newest: ARCH Venture Partners XIII, LLC (director and 10% owner) bought $20M of stock on Jun 22, 2026, filed Jun 24, 2026, scored 51 (moderate). 2 insiders bought within 14 days of each other around Jun 22, 2026.
KARD closed at $14.67 on Oct 9, 2026, 9% above its 52-week low and 43% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Kardigan, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 51Moderate | ARCH Venture Partners XIII, LLC director, owner buy | $20M 1,250,000 shares | +9% | - | |
| 51Moderate | Paul L Berns director, owner buy | $20M 1,250,000 shares | +9% | - |
Transactions
Every row filed, 15 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 29, 2026 | Kristin Marie K Reinke director | AGrant or award Stock Options (right to buy)derivative | +48,368 | $0.00 | $0 | 48,368 | 12 d ago |
| Jun 22, 2026 | ARCH Venture Partners XIII, LLC director, owner | POpen-market purchase Common Stockindirect: By: ARCH Venture Fund XIII, L.P. | +1,250,000 | $16.00 | $20M | 15,042,035 | Jun 24, 2026 |
| Jun 22, 2026 | Paul L Berns director, owner | POpen-market purchase Common Stockindirect: By ARCH Venture Fund XIII, L.P. | +1,250,000 | $16.00 | $20M | 15,042,035 | Jun 24, 2026 |
| Jun 17, 2026 | ARCH Venture Partners XIII, LLC director, owner | CConversion Common Stockindirect: By: ARCH Venture Fund XIII, L.P. | +13,792,035 | - | - | 13,792,035 | Jun 22, 2026 |
| Jun 17, 2026 | Paul L Berns director, owner | CConversion Common Stockindirect: By ARCH Venture Fund XIII, L.P. | +13,792,035 | - | - | 13,792,035 | Jun 22, 2026 |
| Jun 17, 2026 | Jay Edelberg Chief Medical Officer | CConversion Common Stock | +97,587 | - | - | 135,543 | Jun 22, 2026 |
| Jun 17, 2026 | ARCH Venture Partners XIII, LLC director, owner | CConversion Series A Preferred Stockderivativeindirect: By ARCH Venture Fund XIII, L.P. | -5,148,587 | - | - | 0 | Jun 22, 2026 |
| Jun 17, 2026 | Paul L Berns director, owner | AGrant or award Common Stock | +20,706 | $0.00 | $0 | 20,706 | Jun 22, 2026 |
| Jun 17, 2026 | Jay Edelberg Chief Medical Officer | AGrant or award Common Stock | +47,784 | $0.00 | $0 | 183,327 | Jun 22, 2026 |
| Jun 17, 2026 | ARCH Venture Partners XIII, LLC director, owner | CConversion Series B Preferred Stockderivativeindirect: By ARCH Venture Fund XIII, L.P. | -1,204,000 | - | - | 0 | Jun 22, 2026 |
| Jun 17, 2026 | Paul L Berns director, owner | CConversion Series A Preferred Stockderivativeindirect: By ARCH Venture Fund XIII, L.P. | -5,148,587 | - | - | 0 | Jun 22, 2026 |
| Jun 17, 2026 | ARCH Venture Partners XIII, LLC director, owner | CConversion Series B-1 Preferred Stockderivativeindirect: By ARCH Venture Fund XIII, L.P. | -2,306,401 | - | - | 0 | Jun 22, 2026 |
| Jun 17, 2026 | Paul L Berns director, owner | CConversion Series B Preferred Stockderivativeindirect: By ARCH Venture Fund XIII, L.P. | -1,204,000 | - | - | 0 | Jun 22, 2026 |
| Jun 17, 2026 | Jay Edelberg Chief Medical Officer | CConversion Series B Preferred Stockderivative | -61,268 | - | - | 0 | Jun 22, 2026 |
| Jun 17, 2026 | Paul L Berns director, owner | CConversion Series B-1 Preferred Stockderivativeindirect: By ARCH Venture Fund XIII, L.P. | -2,306,401 | - | - | 0 | Jun 22, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- ARCH Venture Partners XIII, LLCowner, director
- Paul L Bernsdirector, officer, owner
- Jay EdelbergChief Medical Officer
- Kristin Marie K Reinkedirector
Questions about KARD
Answered from the filings on this page, as of the latest one.
Are insiders buying KARD?
No. In the last 90 days no insider at Kardigan, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade KARD on the open market?
ARCH Venture Partners XIII, LLC (director and 10% owner) bought $20M of KARD on Jun 22, 2026 and filed the Form 4 on Jun 24, 2026. InsiderTell scored 51 (moderate), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at Kardigan, Inc.?
4 people have filed a Form 4 at Kardigan, Inc., among them ARCH Venture Partners XIII, LLC (10% owner and director), Paul L Berns (director, officer and 10% owner), Jay Edelberg (Chief Medical Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.